Fig. 3From: Prognostic value and clinicopathological characteristics of PD-L1 overexpression in non-Hodgkin lymphoma: a meta-analysisForest plots of studies evaluating hazard ratio (HR) with 95% CI of PD-L1 for overall survival (OS) in DLBCLBack to article page